Indian drugmakers can retain US dominance even with tariffs, says industry body

Indian pharmaceutical companies are expected to maintain their strong presence in the U.S. generic drug market despite possible high tariffs from President Donald Trump. The Pharmaceuticals Export Promotion Council of India believes these companies' competitiveness will help them navigate the new environment, although higher tariffs may squeeze the industry’s margins.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/v3DnoHP
via IFTTT